Title Use of common analgesic medications and ovarian cancer survival : results from a pooled analysis in the Ovarian Cancer Association Consortium Permalink

[1]  S. Tworoger,et al.  Abstract B29: Pre- and postdiagnosis analgesic use and ovarian cancer survival. , 2016 .

[2]  J. Freudenheim,et al.  Use of Common Analgesics Is Not Associated with Ovarian Cancer Survival , 2015, Cancer Epidemiology, Biomarkers and Prevention.

[3]  A. deFazio,et al.  Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival. , 2015, Cancer epidemiology.

[4]  Ping Chen,et al.  Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis , 2015, Cancer Causes & Control.

[5]  X. Ye,et al.  Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies , 2014, British Journal of Cancer.

[6]  Shan Li,et al.  Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis , 2014, BMC Medicine.

[7]  M. Pike,et al.  Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. , 2014, Journal of the National Cancer Institute.

[8]  W. M. Smit,et al.  A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  C. Madeddu,et al.  Inflammation and ovarian cancer. , 2012, Cytokine.

[10]  H. Mizunuma,et al.  Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers , 2008, Pathology & Oncology Research.

[11]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.